10-Q · May 7, 2026
Definitive Healthcare's Q1 2026 results showed a revenue of $55.9 million, beating estimates, and an EPS of $0.06, significantly surpassing expectations. Despite these top-line gains, the company reported a substantial…
Earnings analysis · 10-Q
DH earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so quarterly financial trends and reported GAAP metrics cannot be independently assessed…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so quarterly financial trends and reported GAAP metrics cannot be independently assessed from the filing text provided. The principal new disclosure is a material Nasdaq continued-listing risk: the stock must regain a $1.00 bid price by December 15, 2026 after 30 consecutive business days below the threshold. Disclosure controls were effective as of June 30, 2026, and no material internal-control changes were identified during the quarter.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance that required information was recorded, processed, summarized, and reported on time.
-
No material ICFR changes
The filing reports no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Nasdaq delisting compliance risk
The company received a Nasdaq notice after its Class A common stock closed below the $1.00 minimum bid-price requirement for 30 consecutive business days ended June 17, 2026. It has until December 15, 2026, or 180 calendar days from the notice, to regain compliance; failure could lead to delisting, lower liquidity, and reduced access to capital.
Management's outlook
The supplied 10-Q text does not include quantitative revenue or EPS guidance. Numeric outlook was provided separately in the August 10, 2026 earnings release, not in the supplied filing excerpt.
Earlier filings 4
10-K · February 26, 2026
Definitive Healthcare positions itself as a SaaS healthcare commercial intelligence leader with a proprietary dataset and AI layer, serving ~2,330 customers as of December 31, 2025 across three end markets (Life…
10-K · February 27, 2025
Definitive Healthcare positions itself as a SaaS healthcare commercial intelligence leader with a proprietary dataset and A.I. layer built over more than a decade; the company reported approximately 2,500 customers as…
10-Q · August 5, 2024
Definitive Healthcare reported Q2 revenue of $63.737M, up from $60.957M a year earlier (+$2.78M, +4.6%), with gross margin roughly stable at 79.2%. The quarter included a $363.641M goodwill impairment that produced a…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.